ArticleInfection and drug resistance2022
Prevalence of Tuberculosis and the Determinants of Lose to Follow-Up the Treatment for Tuberculosis Patients in Case of Buno Bedele and Ilu Ababor Zones, Oromia, Ethiopia.
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) is a potentially serious infectious disease that mainly affects the lungs. The bacteria, Methods: A retrospective study design is used to analyze the prevalence of tuberculosis and the determinants of lose to follow-up from TB treatment who follow the treatment from 2006 to 2017. The collected data were analyzed using descriptive statistics and statistical model. Results: The study showed that among 375 TB patients, who started TB treatments, about 24.8% were lost to follow-up from TB treatment and 75.2% were censored at the end of the study. The median survival time of TB patients was 199 days. The results from the Log rank test showed that marital status, HIV co-infection, diabetes mellitus, cancer, and anemia cases had a significant difference between the survival experiences at a 5% level of significance. The result of the Cox-proportion hazard model showed that age (p-value=0.002; CI: (0.9831144, 0.9962526)), HIV co-infection (p-value=0.016; CI: (1.112293, 2.774715)), and anemia (p-value=0.021; CI: (1.089895, 2.938783)) had a significant effect on tuberculosis patients' lose to follow-up from TB treatment at a 5% level of significance. Conclusion: From 375 patients who started TB treatments, about 24.8% were lost to follow-up from TB treatment, and 75.2% were censored at the end of the study. The median survival time of TB patients was 199 days. The variables marital status, HIV co-infection, diabetes mellitus, cancer, and anemia cases had a significant difference between the survival experiences survival time of TB patients at a 5% level of significance. The result also showed that age, HIV co-infection, and anemia had a significant effect on tuberculosis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.